O	0	11	Prescribing
O	12	21	tamoxifen
O	22	24	in
O	25	32	primary
O	33	37	care
O	38	41	for
O	42	45	the
O	46	56	prevention
O	57	59	of
O	60	66	breast
O	67	73	cancer
O	73	74	:
O	75	76	a
O	77	85	national
O	86	92	online
O	93	99	survey
O	100	102	of
B-intervention	103	106	GPs
I-intervention	106	107	'
I-intervention	108	117	attitudes
O	117	118	.

O	119	122	The
O	123	129	cancer
O	130	138	strategy
O	139	142	for
O	143	150	England
O	151	152	(
O	152	156	2015
O	156	157	-
O	157	161	2020
O	161	162	)
O	163	173	recommends
O	174	177	GPs
O	178	187	prescribe
O	188	197	tamoxifen
O	198	201	for
O	202	208	breast
O	209	215	cancer
O	216	223	primary
O	224	234	prevention
O	235	240	among
B-eligibility	241	246	women
I-eligibility	247	249	at
I-eligibility	250	259	increased
I-eligibility	260	264	risk
O	264	265	.

O	266	268	To
O	269	280	investigate
O	281	284	GPs
O	284	285	'
O	286	295	attitudes
O	296	303	towards
O	304	315	prescribing
O	316	325	tamoxifen
O	325	326	.

O	327	329	In
O	330	332	an
O	333	339	online
O	340	346	survey
O	346	347	,
O	348	351	GPs
O	352	354	in
B-location	355	362	England
O	362	363	,
B-location	364	372	Northern
I-location	373	380	Ireland
O	380	381	,
O	382	385	and
B-location	386	391	Wales
O	392	393	(
O	393	394	n
O	395	396	=
B-total-participants	397	400	928
O	400	401	)
O	402	406	were
O	407	417	randomised
O	418	423	using
O	424	425	a
O	426	427	2
O	428	429	Ã—
O	430	431	2
O	432	439	between
O	439	440	-
O	440	448	subjects
O	449	455	design
O	456	458	to
O	459	463	read
O	464	467	one
O	468	470	of
O	471	475	four
O	476	485	vignettes
O	486	496	describing
O	497	498	a
O	499	506	healthy
O	507	514	patient
O	515	522	seeking
O	523	524	a
O	525	534	tamoxifen
O	535	547	prescription
O	547	548	.

O	549	551	In
O	552	555	the
O	556	564	vignette
O	564	565	,
O	566	569	the
O	570	582	hypothetical
O	583	590	patient
O	590	591	'
O	591	592	s
O	593	599	breast
O	600	606	cancer
O	607	611	risk
O	612	613	(
O	613	621	moderate
O	622	628	versus
O	629	633	high
O	633	634	)
O	635	638	and
O	639	642	the
O	643	652	clinician
O	653	663	initiating
O	664	667	the
O	668	680	prescription
O	681	682	(
O	682	684	GP
O	685	695	prescriber
O	696	702	versus
B-control	703	712	secondary
I-control	713	717	care
I-control	718	727	clinician
I-control	728	729	[
I-control	729	732	SCC
I-control	732	733	]
I-control	734	744	prescriber
O	744	745	)
O	746	750	were
O	751	762	manipulated
O	763	765	in
O	766	767	a
O	768	769	1
O	769	770	:
O	770	771	1
O	771	772	:
O	772	773	1
O	773	774	:
O	774	775	1
O	776	781	ratio
O	781	782	.

O	783	791	Outcomes
O	792	796	were
O	797	808	willingness
O	809	811	to
O	812	821	prescribe
O	821	822	,
O	823	830	comfort
O	831	841	discussing
O	842	847	harms
O	848	851	and
O	852	860	benefits
O	860	861	,
O	862	869	comfort
O	870	878	managing
O	879	882	the
O	883	890	patient
O	890	891	,
O	892	899	factors
O	900	909	affecting
O	910	913	the
O	914	925	prescribing
O	926	934	decision
O	934	935	,
O	936	939	and
O	940	949	awareness
O	950	952	of
O	953	962	tamoxifen
O	963	966	and
O	967	970	the
O	971	979	National
O	980	989	Institute
O	990	993	for
O	994	1000	Health
O	1001	1004	and
O	1005	1009	Care
O	1010	1020	Excellence
O	1021	1022	(
O	1022	1026	NICE
O	1026	1027	)
O	1028	1037	guideline
O	1038	1043	CG164
O	1043	1044	.

O	1045	1049	Half
O	1050	1051	(
B-iv-bin-percent	1051	1053	51
I-iv-bin-percent	1053	1054	.
I-iv-bin-percent	1054	1055	7
I-iv-bin-percent	1055	1056	%
O	1056	1057	)
O	1058	1060	of
O	1061	1064	the
O	1065	1068	GPs
B-outcome	1069	1073	knew
I-outcome	1074	1083	tamoxifen
I-outcome	1084	1087	can
I-outcome	1088	1094	reduce
I-outcome	1095	1101	breast
I-outcome	1102	1108	cancer
I-outcome	1109	1113	risk
O	1113	1114	,
O	1115	1118	and
O	1119	1122	one
O	1122	1123	-
O	1123	1130	quarter
O	1131	1132	(
B-cv-bin-percent	1132	1134	24
I-cv-bin-percent	1134	1135	.
I-cv-bin-percent	1135	1136	1
I-cv-bin-percent	1136	1137	%
O	1137	1138	)
O	1139	1143	were
B-outcome	1144	1149	aware
I-outcome	1150	1152	of
I-outcome	1153	1157	NICE
I-outcome	1158	1167	guideline
I-outcome	1168	1173	CG164
O	1173	1174	.

O	1175	1185	Responders
O	1186	1191	asked
O	1192	1194	to
O	1195	1203	initiate
O	1204	1215	prescribing
O	1216	1217	(
O	1217	1219	GP
O	1220	1230	prescriber
O	1230	1231	)
O	1232	1236	were
O	1237	1241	less
B-outcome	1242	1249	willing
I-outcome	1250	1252	to
I-outcome	1253	1262	prescribe
I-outcome	1263	1272	tamoxifen
O	1273	1277	than
O	1278	1283	those
O	1284	1294	continuing
O	1295	1296	a
O	1297	1309	prescription
O	1310	1319	initiated
O	1320	1322	in
O	1323	1332	secondary
O	1333	1337	care
O	1338	1339	(
O	1339	1342	SCC
O	1343	1353	prescriber
O	1353	1354	)
O	1355	1356	(
B-iv-bin-percent	1356	1358	68
I-iv-bin-percent	1358	1359	.
I-iv-bin-percent	1359	1360	9
I-iv-bin-percent	1360	1361	%
O	1362	1368	versus
B-cv-bin-percent	1369	1371	84
I-cv-bin-percent	1371	1372	.
I-cv-bin-percent	1372	1373	6
I-cv-bin-percent	1373	1374	%
O	1374	1375	,
O	1376	1377	P
O	1377	1378	<
O	1378	1379	0
O	1379	1380	.
O	1380	1383	001
O	1383	1384	)
O	1384	1385	.

O	1386	1389	The
O	1390	1392	GP
O	1393	1404	prescribers
O	1405	1413	reported
B-outcome	1414	1418	less
I-outcome	1419	1426	comfort
I-outcome	1427	1437	discussing
I-outcome	1438	1447	tamoxifen
O	1448	1449	(
B-iv-bin-percent	1449	1451	53
I-iv-bin-percent	1451	1452	.
I-iv-bin-percent	1452	1453	4
I-iv-bin-percent	1453	1454	%
O	1455	1461	versus
B-cv-bin-percent	1462	1464	62
I-cv-bin-percent	1464	1465	.
I-cv-bin-percent	1465	1466	5
I-cv-bin-percent	1466	1467	%
O	1467	1468	,
O	1469	1470	P
O	1471	1472	=
O	1473	1474	0
O	1474	1475	.
O	1475	1477	01
O	1477	1478	)
O	1478	1479	.

O	1480	1483	GPs
O	1484	1491	willing
O	1492	1494	to
O	1495	1504	prescribe
O	1505	1509	were
O	1510	1514	more
O	1515	1521	likely
O	1522	1524	to
O	1525	1527	be
O	1528	1533	aware
O	1534	1536	of
O	1537	1540	the
O	1541	1545	NICE
O	1546	1555	guideline
O	1556	1557	(
O	1557	1558	P
O	1559	1560	=
O	1561	1562	0
O	1562	1563	.
O	1563	1566	039
O	1566	1567	)
O	1568	1571	and
O	1572	1574	to
O	1575	1579	have
O	1580	1592	acknowledged
O	1593	1596	the
O	1597	1605	benefits
O	1606	1608	of
O	1609	1618	tamoxifen
O	1619	1620	(
O	1620	1621	P
O	1621	1622	<
O	1622	1623	0
O	1623	1624	.
O	1624	1627	001
O	1627	1628	)
O	1628	1629	,
O	1630	1633	and
O	1634	1638	were
O	1639	1643	less
O	1644	1650	likely
O	1651	1653	to
O	1654	1658	have
O	1659	1669	considered
O	1670	1673	its
O	1674	1677	off
O	1677	1678	-
O	1678	1685	licence
O	1686	1692	status
O	1693	1694	(
O	1694	1695	P
O	1695	1696	<
O	1696	1697	0
O	1697	1698	.
O	1698	1701	001
O	1701	1702	)
O	1702	1703	.

O	1704	1714	Initiating
O	1715	1724	tamoxifen
O	1725	1738	prescriptions
O	1739	1742	for
O	1743	1753	preventive
O	1754	1761	therapy
O	1762	1764	in
O	1765	1774	secondary
O	1775	1779	care
O	1780	1786	before
O	1787	1793	asking
O	1794	1797	GPs
O	1798	1800	to
O	1801	1809	continue
O	1810	1813	the
O	1814	1821	patient
O	1821	1822	'
O	1822	1823	s
O	1824	1828	care
O	1829	1832	may
O	1833	1841	overcome
O	1842	1846	some
O	1847	1858	prescribing
O	1859	1867	barriers
O	1867	1868	.
